Twist Bioscience Corp
Twist Bioscience Corporation (Nasdaq: TWST) develops and manufactures synthetic DNA and related products using a proprietary platform that writes DNA on silicon chips. Its offerings include synthetic genes and gene fragments, oligonucleotide pools, RNA and proteins, next-generation sequencing (NGS) sample-preparation… From the company’s description.
In fiscal 2025, Twist Bioscience Corp reported revenue of $376.57M, up 20.3% from fiscal 2024, and a net loss of $77.67M. Its operating margin was −36.2%, and operations used $47.63M in cash. Over the twelve months to Jun 30, 2026, revenue was $431.80M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Twist Bioscience Corp does
In the company’s own words
Twist Bioscience Corporation (Nasdaq: TWST) develops and manufactures synthetic DNA and related products using a proprietary platform that writes DNA on silicon chips. Its offerings include synthetic genes and gene fragments, oligonucleotide pools, RNA and proteins, next-generation sequencing (NGS) sample-preparation tools, and biopharma services for antibody discovery, optimization and development. Customers include biotechnology and pharmaceutical companies, diagnostic companies, hospitals, research institutions, agricultural and industrial businesses, and academic laboratories. The company serves healthcare, chemicals and materials, academic research, and food and agriculture markets, and reports its business through synthetic biology products, NGS tools, and biopharma services. Its products support applications ranging from drug discovery and disease testing to crop research and development of chemicals and materials. In fiscal 2025, Twist served more than 3,800 customers and generated $376.6 million in revenue; it had 979 employees as of September 30, 2025. Its website is www.twistbioscience.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- SOUTH SAN FRANCISCO, CA
- Fiscal year end
- September
- CIK
- 1581280
- SIC
- 2836
Financial performance, year by year
Fiscal 2019–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Twist Bioscience Corp — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in Twist Bioscience Corp · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · Twist Bioscience Corp’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Twist Bioscience Corp and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Twist Bioscience Corp's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Twist Bioscience Corp's last four quarterly filings that the numbers alone won't show?”